This website is intended for healthcare professionals only

Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Personalized and predictive dermatology recognizes that each patient is unique and aims to comprehensively address all aspects of an individual’s skin health. This approach tailors skin care treatments based on a combination of factors, including genetic and epigenetic profiles, skin type, microbiome composition and the exposome (an individual’s lifetime exposures).1 Scientists are exploring how ecological […]

EADV 2026: Key updates in the field of laser and energy-based devices

Ashraf Badawi
5 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
EADV 2026
Published Online: Oct 14th 2026

From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices.


Expert Insights EADV


Ashraf Badawi New concepts and new directions for lasers and energy-based devices featured across several sessions at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including this year’s European Society for Lasers and Energy Based Devices in Dermatology (ESLD) session.

We spoke with ESLD President and session chair Prof. Ashraf Badawi (Oakville, Canada) to hear his highlights and key takeaways for clinicians. From potential applications in pruritus and cutaneous neurofibromas to optimizing the management of burn scars, there was plenty to discuss about the expanding role of these technologies beyond aesthetic applications.

Prof. Badawi also shared highlights from the Lasers and energy-based devices updates session and discussed his current research into radiofrequency microneedling.


Q. Which emerging applications and approaches stood out in the ESLD session?

read more

Transcript: We had a very rich session, with talks covering a range of applications. One of the interesting talks was about treating pruritus with a fractional CO₂ laser (Samia Esmat, Cairo, Egypt). This was new to me, and it was interesting to learn that we can use a laser to address a problem like this.

For people living with pruritus, this can be a very irritating feeling. And in many cases, this is not alleviated by the normal medications, the classical medications like antihistamines and so on. So, to know that a procedure like a CO₂ laser, used in a mild way, can improve this situation is excellent.

The other thing is, there was a nice talk about using picosecond lasers to treat skin problems like pigmentation (Ahmed Sadek, Cairo, Egypt). This is the classic use. But also using them for rejuvenation and improving the quality of the skin, with a mode which is not associated with downtime or complications, even in dark or tanned skin. This was a new development in the field of lasers.

On the other hand, there was a very interesting talk about how early we can use the laser after trauma and after burns in order to avoid the scarring (Abeer Tawfik, October City, Egypt). Studies now are showing that we are supposed to start treatment very early, in the first few weeks after the injury to the skin, as opposed to what we have been doing for many years, which was to wait 6 months after the trauma. But now the understanding is different, and we have to start much earlier.

There was an interesting talk about using high-intensity focused ultrasound (HIFU) in cutaneous neurofibromas, which highlighted how, instead of using HIFU only for rejuvenation, we can potentially use it to treat certain skin diseases (Katrine Elisabeth Karmisholt, Copenhagen, Denmark). I believe this is a great concept because, when HIFU has been used for rejuvenation, it sometimes causes scarring. However, when the aim of treatment is to destroy certain tissue in the skin without damaging the surface of the skin, then this could be a great application for HIFU. So again, this is a new concept in a different direction.

In summary, I believe those dermatologists who attended the ESLD session yesterday came out of the room with some very nice concepts to implement in practice, starting from tomorrow.

Note: This transcript has been lightly edited with AI assistance (ChatGPT v6.1 Sol) to ensure clarity.


Q. What were your key take-home messages from the laser and energy-based devices session?

The first two talks of the session, which focused on ablative (Sarah Elyoussfi, London, UK) and nonablative lasers (Raphaël André, Geneva, Switzerland), explored how these treatments may influence gene expression. This is an interesting concept, first introduced around 15 years ago, when we began to demonstrate that certain skin treatments could alter gene expression, reducing the activity of genes that become more active with age and increasing the activity of genes that become less active as we age.

These changes can help restore a more youthful pattern of gene expression, representing a form of skin rejuvenation. It is therefore important for practitioners to distinguish between procedures that aim to restore the skin’s structure and function and those that offer a short-term improvement in appearance.

When we inject botulinum toxins or fillers, we can improve the skin’s appearance, but the underlying aging process continues. Without addressing the associated changes in skin structure and function, these will continue to deteriorate over time. By contrast, procedures that target different layers of the skin with the aim of restoring their structure and function may achieve a more regenerative effect. Changes in gene expression provide further evidence of the potential for these treatments to promote skin rejuvenation.

During the session, I also gave a talk on radiofrequency (RF) and plasma devices. I began by asking, “Do you know when the first RF device was introduced?” No one answered, but it was 2002, while the first plasma device was introduced in 1995. These technologies have therefore been around for many years, although interest in them often fluctuates with marketing trends.

Some technologies become very popular, only to fall out of favor when they fail to deliver the promised results or concerns emerge about potential harm to the skin. They may then return with a new marketing campaign, generating renewed interest.

My aim was to explain the scientific principles behind these devices and their limitations, helping practitioners distinguish evidence-based claims from marketing messages so they can set realistic, scientifically grounded expectations.


Q. What prompted your research into radiofrequency microneedling, and what are you aiming to clarify?

We are currently preparing an article on radiofrequency microneedling. Having used this technology for many years, I consider it a valuable option for improving skin quality and treating certain skin conditions. However, the FDA safety communication issued about a year ago prompted me to explore the reasons behind the reported complications,1 including whether aggressive treatment parameters, device quality, or treatment protocols may have contributed.

Our research aims to examine the efficacy and safety of radiofrequency microneedling and the factors that influence treatment outcomes. This includes understanding the condition being treated, recognizing the technology’s limitations and developing appropriate treatment protocols. We also want to highlight what practitioners should avoid to help minimize the risk of complications.


Meeting information: This information was presented at the EADV Congress 2026, Vienna, Austria, September 30–October 3, 2026.

References:

  1. US Food and Drug Administration. Potential risks with certain uses of radiofrequency (RF) microneedling: FDA safety communication. 2025. Available at: www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication (accessed October 13, 2026).

Cite: EADV 2026: Key updates in the field of laser and energy-based devices. touchDERMATOLOGY. 15 October, 2026.

Disclosures: No funding was received for the publication of this content. Thank you to Prof. Dr Ashraf Badawi for sharing her expert insights. Prof. Badawi is the President of the ESLD.

Editor: Gina Furnival, Head of Content

touchDERMATOLOGY coverage of EADV 2026: This content has been developed independently by Touch Medical Media for touchDERMATOLOGY. touchDERMATOLOGY was an official media partner of the EADV Congress 2026. touchDERMATOLOGY is not affiliated with the EADV. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Open Nav
touchConference Hub
Section 2 of 3 Part 8 of 9

touchDERMATOLOGY coverage of EADV Congress 2026

Prev Part
Next Part
touchConference Hub

touchDERMATOLOGY coverage of EADV Congress 2026

Late-breaking data

Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham
Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham

Further APEX data supports zumilokibart’s potential as a less frequent dosing option for atopic dermatitis

Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter

Abdakibart in hidradenitis suppurativa: What we learned from LOTUS

Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
Safety of dupilumab in pregnancy explored in final registry results
Safety of dupilumab in pregnancy explored in final registry results

Safety of dupilumab in pregnancy explored in final registry results

For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.

JAKPPPOT investigates the feasibility of a definitive JAKi trial in palmoplantar pustulosis

Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
0 mins

Topical RLS-1496 reduces actinic keratosis lesion counts

RLS-1496 1% cream is an investigational senotherapeutic treatment that inhibits GPX4. It aims to target senescent cells, potentially offering a new approach to treating actinic keratosis (AK). Encouraging findings from a phase 1b/2a, multicenter, open-label study were presented at EADV 2026. We spoke with Dr Mary Spellman, who presented the findings, about the results and their implications for the treatment’s future development.
Show All...
Currently viewing

Expert insights

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial
Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
Mario Valenti, bimekizumab in hidradenitis suppurativa
Mario Valenti, bimekizumab in hidradenitis suppurativa

Real-world outcomes of bimekizumab in hidradenitis suppurativa

How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

Drug repurposing to advance treatment for rare genetic skin diseases

Drug repurposing could offer new treatment opportunities for rare genetic skin diseases. Prof. Dédée Murrell discusses the rationale for exploring existing medicines, progress in epidermolysis bullosa, and how a new trial aims to match treatments to patients’ inflammatory profiles rather than their genetic subtype.
Maria-Angeliki Gkini
Maria-Angeliki Gkini

EADV 2026: Psoriasis highlights and implications for clinical practice

On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

The Women’s Dermatologic Society at EADV 2026

What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.

Could rezpegaldesleukin offer long-term remission in atopic dermatitis?

New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.

EADV 2026 highlights with Dr Melinda Gooderham

What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Ashraf Badawi
Ashraf Badawi

Key updates in the field of laser and energy-based devices

From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices discussed at this years EADV congress.

Study links glucagon-like peptide-1 receptor agonist use with nail disorders

Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
Show All...

News

3 mins

touchDERMATOLOGY announces new media partnership with the EADV Congress

Through our new collaboration, we will work together to increase the visibility of important developments in dermatology, from the latest clinical research and scientific advances to key society news and updates. As part of the partnership, touchDERMATOLOGY will also bring our community independent coverage directly from the EADV Congress, including the latest data, expert perspectives, key clinical takeaways and onsite interviews with leading specialists.
3 mins

Your quick guide to keynote and plenary sessions at EADV 2026

With EADV Congress 2026 just around the corner, there is plenty to look forward to in Vienna from 30 September to 3 October. If you are joining this year, whether onsite or online, the keynote and plenary sessions are well worth making time for in your congress schedule.

Day 1: Late breakers, JAK inhibitors and keynote lecture open EADV 2026

The EADV Congress opens in Vienna on Wednesday, 30 September. Day 1 highlights include a midday plenary, two late-breaking sessions, a focus on JAK inhibitors, and a closing keynote on the COVID-19 pandemic and the infodemic.
Close Popup